Acelyrin's headquarters in Agoura Hills. (courtesy photo) Conejo Valley-based Acelyrin saw shares plummet more than 30% on Nov. 28 after the biotechnology startup announced an error in one of its trials for its main treatment. Acelyrin, which is a part of Westlake Village BioPartners investing portfolio, disclosed there was a programming error in a drug